<DOC>
	<DOC>NCT02859246</DOC>
	<brief_summary>It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.</brief_summary>
	<brief_title>Mucinex® for Treatment of Filamentary Keratitis</brief_title>
	<detailed_description>The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.</detailed_description>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<criteria>Patients with filamentary keratitis 18 years and older Active ocular surface infection of any type Recent ocular surgery (&lt;30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones Schirmer's test&lt;3mm History of hypersensitivity to Mucinex® Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>